Project Grant R44CA250663

Oraliva, Inc. received a $400,000 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded September 1, 2025, with completion targeted for August 31, 2027. The funding supports development of a novel, low-cost point-of-care (POC) gynecological screening diagnostic that combines human papillomavirus (HPV) and cervical cancer detection capabilities. Oraliva is leveraging its proprietary artificial intelligence-linked...

Vigilant Laboratories LLC received a $1,021,347 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop a commercializable point-of-care (POC) early detection test for oral cavity and oropharyngeal squamous cell carcinoma (OOPSCC). The award, effective September 1, 2025, through August 31, 2027, funds the optimization and advancement of patented biomarker technology combining CD44 (stem cancer cell marker), total...

This five-year, $536,955 project grant from the National Cancer Institute, part of the Department of Health and Human Services, will fund research under the Cancer Detection and Diagnosis Research program. The Washington University will develop pre-treatment and recurrence biomarkers for locally advanced cervical cancer by analyzing variance in human papillomavirus genomic structures among patient tumors. Researchers will extract HPV genomic features from matched DNA and RNA sequencing data to...

New York University School of Medicine received a $703,227 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded June 1, 2026, with a completion date of May 31, 2031. The grant supports development of an ultra-rapid droplet digital polymerase chain reaction (ddPCR) technology platform designed to deliver molecular-genetic profiling of cancer-driving mutations directly within the operating room during surgical resection...

Federal Project Grant Award Summary The National Cancer Institute, through its Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded $532,105 to Simplusdx, Inc. on July 1, 2026, to develop and validate a point-of-care (POC) screening test for hepatocellular carcinoma (HCC). The award, which extends through June 30, 2029, will support the finalization and clinical translation of a screening test utilizing the D4 immunoassay platform—a nonfouling poly(oligoethylene glycol methyl...

The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...

The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.395 - Cancer Treatment Research) to Ampedrna Biosciences LLC in the amount of $398,823 to develop a highly immunogenic mini-circular RNA (mcrRNA) therapeutic cancer vaccine for human papillomavirus (HPV)-related cancers. The goal is to create an off-the-shelf or personalized vaccine that can elicit robust and durable T cell responses to target HPV E6 and E7 antigens, which are known to drive HPV-induced cancers. The proposed...

Federal Grant Award Summary Massachusetts Eye and Ear Infirmary received a $642,406 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded June 1, 2026, with completion scheduled for May 31, 2031. The research focuses on developing blood-based early detection methods for viral precancers, specifically utilizing human papillomavirus (HPV) cell-free DNA and fragmentomics analysis. The project aims to create...

Morphogenesis, Inc. was awarded a $1,200,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, to develop a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the United States. The funding supports optimization of Morphogenesis' IFX-HU2.1 plasmid DNA-based cream formulation for temperature stability using established methods and models. In vitro...

Federal Cooperative Agreement Summary The Beckman Research Institute of the City of Hope received a $738,675 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded March 16, 2026, with a completion date of February 28, 2031. The award funds development of an exosome-based liquid biopsy assay designed to enable non-invasive early detection of colorectal adenomas and cancers from a single blood draw. The research...